Cook Jennifer E. sold $2.8M of BBIO

Cook Jennifer E. sold 39,363 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $69.92 ($68.57–$70.00, $2.75M total) across 2 trades over 2026-06-23 to 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Jennifer E.
Published Jun 24, 2026, 10:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosure updates the insider’s recent selling activity (39,363 shares; ~$2.75M total) and confirms it was executed under a Rule 10b5-1 plan.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 framing reduces the likelihood of a strong fundamental read-through.

03

What to watch

Traders may over-weight insider sales; without concurrent guidance/clinical/regulatory updates, the signal is usually limited to short-lived sentiment.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-06-24)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Pharma director Jennifer E. Cook sold 39,363 shares in open-market transactions at ~$68.57–$70.00, per a fresh SEC Form 4 filed today.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing provides transaction size, dates, and pricing, but no new company-specific operating/financial catalyst. 10b5-1 plans typically reduce interpretive signal.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying fundamentals.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish information.

Key entities

  • BridgeBio Pharma, Inc.

    Subject of the Form 4 insider transaction; director Jennifer E. Cook sold shares in open-market trades.

  • Jennifer E. Cook

    Director who executed the reported sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.